ImmunoPrecise Antibodies (IPA) (NASDAQ: IPA) has officially announced the resignation of Brad McConn from his position as Chief Financial Officer, effective September 29, 2023. In response, IPA has appointed Kristin Taylor, MBA, CPA, as the interim Chief Financial Officer.
Dr. James Kuo, Chairman of the Board, expressed his appreciation for Brad’s leadership and contributions while extending best wishes for his future endeavors. Dr. Kuo also welcomed Kristin Taylor as the interim CFO. He emphasized Ms. Taylor’s extensive executive management experience, particularly in the life sciences sector, along with her strong background in capital markets and investor relations. Dr. Kuo expressed confidence in the combined capabilities of Kristin Taylor and IPA’s existing accounting, financial reporting, and treasury teams to ensure a seamless transition in all CFO-related responsibilities.
ImmunoPrecise Antibodies Ltd. operates through various subsidiaries in North America and Europe, including entities like Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V. Collectively known as the “IPA Family,” these subsidiaries form a biotherapeutic research and technology group specializing in systems biology, multi-omics modeling, and complex artificial intelligence systems.
Have you read?
The World’s Top 10 Highest-Paid Wealth Management Executives.
CEO compensation: Highest paid chief executive officers in the United States in 2022.
Highly-Paid Entertainment Chief Executives (Averaged $31.66 Million), 2022.
Highest paid health insurance CEOs.
Most Powerful Companies in Australia, 2023.
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
This report/news/ranking/statistics has been prepared only for general guidance on matters of interest and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, CEOWORLD magazine does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
SUBSCRIBE NEWSLETTER
